CB Therapeutics is an innovative biotechnology company focusing on research and production of cannabinoids. The company utilizes its proprietary biosynthesis process to produce popular phytocannabinoids, such as CBD, THCV, and other rare compounds, not previously available due to the difficulty and cost of extraction from plants.
CB Therapeutics today announces that it is operating a new R&D and production facility in Southern California. The 7K sq. ft. site includes a research lab and a production space for laboratory scale and pilot production runs. The facility comes equipped with a suite of benchtop and large-scale fermenters ready to use in biosynthetic applications. This plug-and-play upgrade for CB Therapeutics greatly accelerates its path to bringing pure, therapeutic compounds to market.
“This is a game-changing update for the CBD biosyn landscape,” said Chief Scientific Officer, Jacob Vogan. “This huge new space dramatically speeds up our scale-up progress and allows us to expand our groundbreaking technology to produce pure cannabinoids and terpenes in a sustainable way.” Sher Butt, the president and CEO of CB Therapeutics added that “traditionally the extraction of cannabinoids from the plant source is a capital intensive endeavor, requiring significant investment in land and infrastructure. Our new facility will allow us to circumvent such a sizable expenditure and materially enhance our efforts to provide high purity CBD and other cannabinoids, in a timely and cost-effective manner.”
View source version on businesswire.com: https://www.businesswire.com/news/home/20190320005823/en/
Contacts:
sher@cbthera.com
